Gordon Jayson qualified in Medicine at the University of Oxford. His subsequent medical and oncology training took place in Manchester and the Christie Hospital. Following a PhD in heparan sulfate biology, he has conducted post-doctoral research that aims to translate the new data from heparan sulfate biology into the clinic. His current programme of work, described above, is directed at the laboratory development of novel oligosaccharides as anti-angiogenic agents and the early and late clinical trial evaluation of this class of drugs. The latter programme aims to identify serological and imaging based biomarkers that will identify the patients who are most likely to benefit from this these agents and which will be used to underpin the development of combination regimens of biological agents. This work is largely focused on ovarian cancer, the disease that Professor Jayson looks after in Christie Hospital.